PAS
ELVN icon

Point72 Asia (Singapore)’s Enliven Therapeutics ELVN Stock Holding History

Point72 Asia (Singapore)’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$56.8K Sell
2,773
-3,815
-58% -$76.9K 0.01% 549
2025
Q2 		$132K Buy
6,588
+4,293
+187% +$81.3K 0.02% 423
2025
Q1 		$45.2K Buy
+2,295
New +$49.4K 0.01% 588

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Point72 Asia (Singapore)'s ELVN Position: Q3 2025 in Review

Point72 Asia (Singapore) reduced its Enliven Therapeutics (ELVN) stake by 58% in Q3 2025, selling an estimated $76.9K and leaving 2,773 shares worth $56.8K. The position accounts for 0.01% of the portfolio, ranked #549.

Point72 Asia (Singapore) first reported a position in ELVN in Q1 2025 and has held it in 3 quarters since. The position peaked at $132K in Q2 2025. 134 funds tracked by Wall St. Rank hold ELVN as of Q3 2025.

  • Point72 Asia (Singapore) held 2,773 shares of Enliven Therapeutics worth $56.8K as of Q3 2025.
  • Point72 Asia (Singapore) sold 3,815 Enliven Therapeutics shares in Q3 2025, an estimated $76.9K.
  • Enliven Therapeutics made up 0.01% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #549 holding.
  • Point72 Asia (Singapore) first reported a position in Enliven Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Point72 Asia (Singapore)'s Enliven Therapeutics position peaked at $132K in Q2 2025.
  • 134 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.